Always private
DuckDuckGo never tracks your searches.
Learn More
You can hide this reminder in Search Settings
All regions
Argentina
Australia
Austria
Belgium (fr)
Belgium (nl)
Brazil
Bulgaria
Canada (en)
Canada (fr)
Catalonia
Chile
China
Colombia
Croatia
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India (en)
Indonesia (en)
Ireland
Israel (en)
Italy
Japan
Korea
Latvia
Lithuania
Malaysia (en)
Mexico
Netherlands
New Zealand
Norway
Pakistan (en)
Peru
Philippines (en)
Poland
Portugal
Romania
Russia
Saudi Arabia
Singapore
Slovakia
Slovenia
South Africa
Spain (ca)
Spain (es)
Sweden
Switzerland (de)
Switzerland (fr)
Taiwan
Thailand (en)
Turkey
Ukraine
United Kingdom
US (English)
US (Spanish)
Vietnam (en)
Safe search: moderate
Strict
Moderate
Off
Any time
Any time
Past day
Past week
Past month
Past year
  1. thelancet.com

    Dec 20, 2023Compared with conventional mRNA-based vaccines, self-amplifying RNA (saRNA) vaccines promise improved and longer-lived potency due to both the amplification of the RNA in vivo and the adjuvating properties of double-stranded RNA and its replication intermediates.1 Inducing protective immune responses by delivering an RNA through a self-amplifying mechanism should therefore require lower doses ...
  2. thelancet.com

    Self-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants. Compared with conventional mRNA-based vaccines, self-amplifying RNA (saRNA) vaccines promise . improved and longer-lived potency due to both the amplification of the RNA in vivo and the adjuvating properties of double-stranded RNA and its replication intermediates. 1
  3. thelancet.com

    Oct 23, 2024A self-amplifying RNA-based vaccine targeting ancestral SARS-CoV-2 was immunogenic as both a priming and booster vaccine in phase 3 trials. 3,4 In a direct comparison with an mRNA-based vaccine, ARCT-154 induced superior neutralising antibody concentrations to omicron BA.5, 4 highlighting the potential of self-amplifying RNA-based vaccines to induce stronger and broader antibody responses.
  4. pmc.ncbi.nlm.nih.gov

    Our results are consistent with the reports for other saRNA vaccines, in which neutralizing antibody titers against Beta, Delta, and Omicron SARS-CoV-2 variants are reduced compared to those against the Wuhan-like virus. 30 It is important to note that it is challenging to compare our data with other recent preclinical studies that evaluated ...
  5. pubmed.ncbi.nlm.nih.gov

    RNA-based vaccines against SARS-CoV-2 have demonstrated promising protective immunity against the global COVID-19 epidemic. ... Enhancing protective immunity against SARS-CoV-2 with a self-amplifying RNA lipid nanoparticle vaccine J Control Release. 2024 Dec 5:S0168-3659(24)00846-. doi: 10.1016/j.jconrel.2024.12.003. Online ahead of print. ...
  6. ncbi.nlm.nih.gov

    National Center for Biotechnology Information

    https://www.ncbi.nlm.nih.gov › pmc › articles › PMC8721936

    RNA vaccines have demonstrated efficacy against SARS-CoV-2 in humans, and the technology is being leveraged for rapid emergency response. In this report, we assessed immunogenicity and, for the first time, toxicity, biodistribution, and protective efficacy in preclinical models of a two-dose self-amplifying messenger RNA (SAM) vaccine, encoding a prefusion-stabilized spike antigen of SARS-CoV ...
  7. pubmed.ncbi.nlm.nih.gov

    Vaccines for SARS-CoV-2 have been hugely successful in alleviating hospitalization and deaths caused by the newly emerged coronavirus that is the cause of COVID. ... A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model ... nor whether variants will ...
  8. pmc.ncbi.nlm.nih.gov

    Self-amplifying mRNA (sa-mRNA) SARS-CoV-2 vaccines containing S protein or S and N proteins raised robust cross-reactive neutralizing antibody and T cell responses against variants in mice. Hamsters immunized with either vaccine were fully protected from lung infection with significantly reduced viral loads in upper respiratory tracts. Introduction
  9. thelancet.com

    Dec 20, 2023In adults who had previously received three doses of an mRNA COVID-19 vaccine, immune responses 28 days after an ARCT-154 booster dose were non-inferior to those observed after a BNT162b2 booster dose for the Wuhan-Hu-1 strain of SARS-CoV-2 and superior for the Omicron BA.4/5 variant. Increased immune responses at 28 days might provide increased likelihood of protection against these strains ...

    Can’t find what you’re looking for?

    Help us improve DuckDuckGo searches with your feedback

Custom date rangeX